View Older Stories View More Recent Stories
-
Pfizer (PFE) Reaffirms FY24 Guidance, Issues FY25 Guidance
-
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
-
Pfizer's (PFE) IBRANCE in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast C
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Pfizer (PFE) PT Lowered to $33 at Guggenheim
-
Pfizer (PFE) PT Lowered to $28 at Leerink Partners
-
Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
-
Trump hosted the chief executives of Pfizer (PFE), Eli Lilly & Co. (LLY) - Axios
-
This big pharma stock offers an 'interesting near-term setup' says Morgan Stanley
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
UK's CMA: Competition Appeal Tribunal Fines Pfizer (PFE) and Flynn GBP 69M for Excessive Pricing
-
Pfizer (PFE) Appoints Chris Boshoff as Chief Scientific Officer and President of R&D
-
Pfizer (PFE) Announces EU Approval of HYMPAVZI for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
-
Pfizer (PFE) call put ratio 1 call to 2.3 puts
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
Pfizer (PFE) Explores Sale Of Hospital Drugs Unit, Hires Goldman Sachs For Advice, Sources Say - Reuters
-
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
-
Popular stocks with increasing volume: SOFI DJT F PFE BA MSTR PYPL SMCI SNAP GME
-
Pfizer (PFE) Meeting With Starboard Was Constructive, Cordial - CEO Bourla
-
Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
-
Pfizer (PFE) call put ratio 3.7 calls to 1 put with focus on November 1 weekly calls into quarter results
-
Pfizer (PFE) call put ratio 3.2 calls to 1 put into quarter results
-
Pfizer (PFE): Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
-
Pfizer (PFE) Announces FDA Approval of ABRYSVO for Adults Aged 18 to 59 at Increased RSV Risk
-
Starboard Value Issues Presentation Delivered at 13D Monitor’s 2024 Active-Passive Investor Summit
-
Pfizer (PFE) Appoints Tim Buckley to its Board
-
Pfizer (PFE) Announces FDA Approval of HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
-
UK MHRA: approved an adapted Pfizer (PFE) /BioNTech (BNTX) Covid-19 vaccine (comirnaty) that targets the KP.2 Covid-19 subvariant for adults
-
Pfizer (PFE) call put ratio 3.9 calls to 1 put with focus on October 11 weekly 30 calls
-
Starboard Value Issues Letter to Pfizer’s (PFE) Board of Directors
-
Pfizer (PFE) Reports TALZENNA in Combination with XTANDI Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
-
Pfizer (PFE) Declares $0.42 Quarterly Dividend; 5.6% Yield
-
Popular stocks with increasing volume: PFE CCL BABA AAL MSTR NIO HOOD SOFI PDD
-
Pfizer (PFE) PT Raised to $31 at CFRA
-
Active options: PFE MSTR PLTR NIO MSFT OXY DJT RIOT BA
-
TD Cowen Reiterates Hold Rating on Pfizer (PFE)
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer (PFE) invalidates two GSK (GSK) RSV vaccine patents in U.K.
-
Leerink Partners Reiterates Market Perform Rating on Pfizer (PFE)
-
Pfizer (PFE) option IV into Starboard has $1B stake and seeks changes, WSJ reports
-
Stocks expected to have increasing option volume: PEP TSLA AMD GM BA PFE PDD JD BABA
-
Activist Starboard Value Takes $1B Stake In Pfizer (PFE) - WSJ
-
Pfizer (PFE) Boosts Haleon (HLN) Offering Size To 640m Shares From 540m - Bloomberg
-
Pfizer (PFE) Intends To Sell About 540M Haleon (HLN) Shares - Bloomberg
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE)
-
Pfizer (PFE) Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA From Worldwide Markets
-
Pfizer (PFE), BioNTech (BNTX) gain positive CHMP opinon on Omicron KP.2-adapted COVID-19 vaccine in EU
-
Midday movers: Intel, Pfizer rise; Apple falls
-
Pfizer (PFE) Presents Positive Data from Phase 2 Study of Ponsegromab
